EFTR (eFFECTOR Therapeutics) Total Liabilities: $26.30 Mil (As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is eFFECTOR Therapeutics Total Liabilities?

eFFECTOR Therapeutics EFTR Total Liabilities is $26.30 Mil as of Mar. 2024.

eFFECTOR Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $26.30 Mil.

eFFECTOR Therapeutics's quarterly Total Liabilities increased from Sep. 2023 ($24.13 Mil) to Dec. 2023 ($26.34 Mil) but then declined from Dec. 2023 ($26.34 Mil) to Mar. 2024 ($26.30 Mil).

eFFECTOR Therapeutics's annual Total Liabilities declined from Dec. 2021 ($36.77 Mil) to Dec. 2022 ($25.18 Mil) but then increased from Dec. 2022 ($25.18 Mil) to Dec. 2023 ($26.34 Mil).


eFFECTOR Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for eFFECTOR Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

eFFECTOR Therapeutics Total Liabilities Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Liabilities
148.95 36.77 25.18 26.34

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.74 24.31 24.13 26.34 26.30

eFFECTOR Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

eFFECTOR Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=20.544--5.795
=26.34

eFFECTOR Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=25.569+(0.179+0.556
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=26.30

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=27.131-0.827
=26.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $26.30 Mil mean?
eFFECTOR Therapeutics (EFTR) has a Total Liabilities of $26.30 Mil as of Mar. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for eFFECTOR Therapeutics and its competitors.
Is eFFECTOR Therapeutics' Total Liabilities too high?
eFFECTOR Therapeutics' current Total Liabilities is $26.30 Mil.
How does eFFECTOR Therapeutics' Total Liabilities compare to NTBLQ and MTEM?
eFFECTOR Therapeutics' Total Liabilities of $26.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for eFFECTOR Therapeutics and its competitors. eFFECTOR Therapeutics's current Total Liabilities is $26.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is eFFECTOR Therapeutics stock overvalued right now?
eFFECTOR Therapeutics (EFTR) has a current Total Liabilities of $26.30 Mil. The current Total Liabilities is $26.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For eFFECTOR Therapeutics (EFTR), the current Total Liabilities is $26.30 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

eFFECTOR Therapeutics Business Description

Address 142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).